Tvardi Therapeutics, Inc. Common Stock
TVRDTvardi Therapeutics, Inc. is a biotechnology company focused on developing targeted therapies for inflammatory and fibrotic diseases. The company leverages its proprietary drug discovery platform to identify and advance small-molecule treatments aimed at challenging conditions, with an emphasis on improving patient outcomes.
$3.90 +0.05 (1.20%)
Company News
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
Tvardi Therapeutics experienced an 80% stock drop after disappointing Phase 2 clinical trial results for TTI-101 in idiopathic pulmonary fibrosis, with preliminary data showing the study did not meet its goals.
